Immunome Inc (IMNM NASDAQ) stock market data APIs
$10.3
0.35(3.5%)
as of January 24, 2025
Immunome Inc Financial Data Overview
Price chart is built with
Anychart
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Prev. Close
9.95
Open
10.3
Volume
527 K
High
10.4111
Low
9.89
52 wk Range
8.97-30.958
Market Cap
638 M
Shares Outstanding
62 417 K
Revenue
10 129 K
EPS
-0.78
Beta
1.822
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Immunome Inc data using free add-ons & libraries
Get Immunome Inc Fundamental Data
Immunome Inc Fundamental data includes:
- Net Revenue: 10 129 K
- EBITDA: -110 441 000
- Earnings Per Share: -7
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-07
- EPS/Forecast: -0.56
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Immunome Inc News
New
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
- Exclusive worldwide license agreement for preclinical ROR1 ADC, on track to submit IND in 1Q 2025 - - Proprietary ADC platform enhances Immunome’s development of next-generation ADC programs - -...
Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
Atreca, Inc. CAMPBELL, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (“Atreca”) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a uniqu...
7 Biotech Stocks to Get In Now Before Investors Catch On
Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles happen with living organisms. Immunotherapies promi...
Moore Kuehn Encourages CELL, CCF, IMNM, and KLR Investors to Contact Law Firm
NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims conce...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
